{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VHL&page=2",
    "query": {
      "condition": "VHL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VHL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:43:17.995Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001238",
      "title": "Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Cancer",
        "Urologic Malignant Disorders",
        "Renal Cell Carcinoma",
        "Familial Renal Cancer (FRC)",
        "Clear Cell Renal Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "1990-12-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001238"
    },
    {
      "nct_id": "NCT02315625",
      "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Neuroendocrine Carcinoma",
        "Neuroendocrine Neoplasms",
        "Carcinoma, Neuroendocrine",
        "Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-04-08",
      "completion_date": "2019-05-22",
      "has_results": true,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315625"
    },
    {
      "nct_id": "NCT01496625",
      "title": "National Eye Institute Biorepository for Retinal Diseases",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Diabetic Retinopathy",
        "Von Hippel-Lindau Syndrome",
        "Retinal Disease",
        "Retinal Vein Occlusion"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "2 Years to 120 Years"
      },
      "enrollment_count": 650,
      "start_date": "2012-06-18",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496625"
    },
    {
      "nct_id": "NCT01266070",
      "title": "TKI 258 in Von Hippel-Lindau Syndrome (VHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Von Hippel-Lindau Syndrome"
      ],
      "interventions": [
        {
          "name": "Dovitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2012-11",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-13",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266070"
    },
    {
      "nct_id": "NCT00470977",
      "title": "Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coats' Disease",
        "Idiopathic Retinal Telangiectasia",
        "Retinal Angiomatous Proliferation",
        "Polypoidal Choroidal Vasculopathy",
        "Pseudoxanthoma Elasticum",
        "Pathological Myopia",
        "Multi-focal Choroiditis",
        "Rubeosis Iridis",
        "Von Hippel Lindau Disease",
        "BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)"
      ],
      "interventions": [
        {
          "name": "ranibizumab injection (0.5 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manhattan Eye, Ear & Throat Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470977"
    },
    {
      "nct_id": "NCT01967576",
      "title": "Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pheochromocytoma",
        "Paraganglioma"
      ],
      "interventions": [
        {
          "name": "Axitinib (AG-013736)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-10-19",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01967576"
    },
    {
      "nct_id": "NCT04074135",
      "title": "Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL Pancreatic Neuroendocrine Tumors",
        "Von Hippel-Lindau Disease",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "68-Gallium DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 740,
      "start_date": "2020-06-02",
      "completion_date": "2036-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04074135"
    },
    {
      "nct_id": "NCT06322342",
      "title": "Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System (CNS) Lesions",
        "Brain Metastases",
        "Brain Neoplasms",
        "Brain Neoplasms, Benign",
        "Brain Tumor, Primary",
        "Brain Tumor, Recurrent",
        "Brain Tumors",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Neoplasm, Primary",
        "Multiple Sclerosis",
        "Multiple Sclerosis Brain Lesion",
        "Neurofibroma",
        "Acoustic Neuroma",
        "CNS Tumor",
        "CNS Lesion",
        "CNS Metastases",
        "CNS Cancer",
        "CNS Lymphoma",
        "Von Hippel Lindau",
        "Meningioma",
        "Glioma",
        "Schwannomas",
        "Neuroinflammation",
        "Neoplasia"
      ],
      "interventions": [
        {
          "name": "RVP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reveal Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-15",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06322342"
    },
    {
      "nct_id": "NCT03401788",
      "title": "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL - Von Hippel-Lindau Syndrome",
        "VHL Gene Mutation",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "VHL-Associated Renal Cell Carcinoma",
        "VHL-Associated Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-05-02",
      "completion_date": "2027-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 8,
      "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401788"
    },
    {
      "nct_id": "NCT03001349",
      "title": "68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Meningioma",
        "Metastatic Well Differentiated Neuroendocrine Neoplasm",
        "Multiple Endocrine Neoplasia Type 1",
        "Neuroendocrine Neoplasm",
        "Somatostatin Positive Neoplastic Cells Present",
        "Von Hippel-Lindau Syndrome"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-Edotreotide",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2017-05-16",
      "completion_date": "2021-02-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-05-22T05:43:17.995Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03001349"
    }
  ]
}